The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic

Journal of Cerebral Blood Flow and Metabolism

Volumn 29, Issue 1, 2009, Pages 66-72

  Abe, Takato ^a   Kunz, Alexander ^a   Shimamura, Munehisa ^a   Zhou, Ping ^a   Anrather, Josef ^a   Iadecola, Costantino ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Corner test; Cyclooxygenase; Middle cerebral artery occlusion; Prostanoids; SC51089

Indexed keywords

8CHLORODIBENZ 11 [1,4]OXAZEPINE 10 (11H) CARBOXYLIC ACID; PROSTAGLANDIN E2; RECEPTOR BLOCKING AGENT; SC 51089; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE;

ANIMALS; BODY WEIGHT; BRAIN ISCHEMIA; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDRAZINES; MALE; MICE; NEUROPROTECTIVE AGENTS; OXAZEPINES; RECEPTORS, PROSTAGLANDIN E; SEX CHARACTERISTICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149172167     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2008.88     Document Type: Article

References (38)

1. Ahmad AS, Saleem S, Ahmad M, Dore S (2006) Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89:265-70
2. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015-20
3. Beaulieu C, Busch E, Rother J, de Crespigny A, Hsia CJ, Moseley ME (1998) Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat: potential mechanisms studied by magnetic resonance imaging. J Cereb Blood Flow Metab 18:1022-1031
4. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9:1180-6
5. Bouet V, Freret T, Toutain J, Divoux D, Boulouard M, Schumann-Bard P (2007) Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol 203:555-67
6. Carlson NG (2003) Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res 71:79-88
7. Cho S, Park EM, Febbraio M, Anrather J, Park L, Racchumi G, Silverstein RL, Iadecola C (2005) The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 25:2504-12
8. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein GZ (1993) Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Res Bull 31:565-72
9. Corbett D, Nurse S (1998) The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog Neurobiol 54:531-48
10. Dietrich WD, Busto R, Alonso O, Globus MY, Ginsberg MD (1993) Intraischemic but not postischemic brain hypothermia protects chronically following global forebrain ischemia in rats. J Cereb Blood Flow Metab 13:541-9
11. Dirnagl U (2006) Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 26:1465-78
12. Drummond JC, Piyash PM, Kimbro JR (2000) Neuroprotection failure in stroke. Lancet 356:1032-3
13. Gladstone DJ, Black SE, Hakim AM (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123-36
14. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley Jr EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-74
15. Hallinan EA, Hagen TJ, Tsymbalov S, Husa RK, Lee AC, Stapelfeld A, Savage MA (1996) Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. J Med Chem 39:609-13
16. Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-66
17. Hattori K, Lee H, Hurn PD, Crain BJ, Traystman RJ, DeVries AC (2000) Cognitive deficits after focal cerebral ischemia in mice. Stroke 31:1939-44
18. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL (2003) Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34:1106-13
19. Hurn PD, Vannucci SJ, Hagberg H (2005) Adult or perinatal brain injury: does sex matter? Stroke 36:193-5
20. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-9
21. Khaja AM, Grotta JC (2007) Established treatments for acute ischaemic stroke. Lancet 369:319-30
22. Kunz A, Park L, Abe T, Gallo EF, Anrather J, Zhou P, Iadecola C (2007) Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci 27:7083-93
23. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD (2004) Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol 187:94-104
24. Lin TN, He YY, Wu G, Khan M, Hsu CY (1993) Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 24:117-21
25. Minghetti L (2007) Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem 42:127-141
26. NINDS (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333:1581-7
27. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59:467-77
28. Park EM, Cho S, Frys KA, Glickstein SB, Zhou P, Anrather J, Ross ME, Iadecola C (2006) Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury. J Cereb Blood Flow Metab 26:392-401
29. Plesnila N, Zinkel S, Le DA, Amin-Hanjani S, Wu Y, Qiu J, Chiarugi A, Thomas SS, Kohane DS, Korsmeyer SJ, Moskowitz MA (2001) BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci USA 98:15318-15323
30. Reeves MJ, Broderick JP, Frankel M, LaBresh KA, Schwamm L, Moomaw CJ, Weiss P, Katzan I, Arora S, Heinrich JP, Hickenbottom S, Karp H, Malarcher A, Mensah G (2006) The Paul Coverdell National Acute Stroke Registry: initial results from four prototypes. Am J Prev Med 31:S202-9
31. Sena E, van der Worp HB, Howells D, Macleod M (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30:433-9
32. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437
33. STAIR (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-8
34. Valtysson J, Hillered L, Andine P, Hagberg H, Persson L (1994) Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. Acta Neurochir (Wien) 129:58-63
35. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Narumiya S, Sugimura T, Wakabayashi K (2000) Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 156:57-61
36. Zhang F, Iadecola C (1994) Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J Cereb Blood Flow Metab 14:574-80
37. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, Lu M, Chopp M (2002) A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods 117:207-14
38. Zhou P, Qian L, Chou T, Iadecola C (2008) Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 29:543-51